DR. TEERLINK: Powered appropriately for cardiovascular endpoints?
DR. WOLF: Yes.
DR. TEERLINK: Thank you.
DR. BURMAN: Any questions?
I have some questions and I don't know who would be the best person.
that's largely due to cardiovascular issues, concerns about other agents along those
lines, and I am confused then how if we are doing a post marketing study, the post
marketing analysis compared to these other agents where one of the major concerns is
cardiovascular events, how we are going to get any information on a post marketing
study that's not randomized to comparing it to things where there is potential for
cardiovascular concern, I don't know how I am going to be comforted by that?
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com
DR. WOLF: We intend to do randomized clinical assessments of this
the second is what other actions does it have and third is when you knockout mice for
DPP-4 what other problems do they end up with?
Some of them relate to physiology. The first question is a simple one, where does DPP-4
come from, which organ and related to that is, does it have any other actions and what
happens in knockout mice where DPP-4 is knocked out?
DR. WOLF: I would like to ask Dr. Mark Curby to come to come to the
podium please, or Dr. Garrell please. Thank you.
DR. BURMAN: Of course. The first is what's the source of DPP-4 and
DR. GARRELL: So I am Mark Garrell from the University of Sydney.
Could I get the questions repeated please, I think there was two or three.